Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Jun;31(6):253-8.
doi: 10.1002/clc.20181.

Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level

Kuei-Chuan Chan  1 , Hsi-Hsien Chou, Chien-Ning Huang, Ming-Chih Chou
Affiliations
Randomized Controlled Trial

Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level

Kuei-Chuan Chan et al. Clin Cardiol. 2008 Jun.

Abstract

Background: There is controversy about the effects of statins on plasma adiponectin, and the impact of percutaneous coronary intervention (PCI) on plasma adiponectin level is still unknown. We investigated the impact of Atorvastatin on plasma adiponectin levels in coronary artery disease (CAD) patients with stable angina and normal lipid profiles after PCI.

Methods: Sixty CAD patients with stable angina and normal lipid profiles scheduled for PCI, and not on statins, were randomly assigned to either no treatment (control group) or the Atorvastatin treatment (Atorvastatin group). Atorvastatin administration was started immediately after PCI. Blood samples were obtained immediately after PCI and again 3 and 6 mo later. Fasting plasma adiponectin concentrations were measured using a radioimmunoassay kit.

Results: After PCI, there were statistically significant decreases in adiponectin levels in the Atorvastatin group at 3 and 6 mo (8.66 +/- 0.69 versus 6.87 +/- 0.55 and 7.12 +/- 0.71 microg/mL at 0, 3, and 6 mo, respectively), despite the anti-inflammation and lipid-lowering effects of Atorvastatin. There were no statistically significant changes in adiponectin levels in the control group. There was significant positive association between baseline plasma adiponectin and high-density lipoprotein (HDL) levels. Changes of adiponectin level were not associated with the changes of high-sensitivity C-reactive protein (hs-CRP) and lipid profiles in the Atorvastatin group.

Conclusions: Our study confirmed the benefits of Atorvastatin on anti-inflammation and anti-atherosclerosis, but we also found that Atorvastatin had a negative effect on the adiponectin system. The anti-inflammatory, anti-atherogenic effects of Atorvastatin are not affected by decreased adiponectin levels.

PubMed Disclaimer

References

    1. Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, et al.: Scottish Multicentre Study of diabetes pregnancy: adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care 2003; 26: 2244–2249. - PubMed
    1. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, et al.: Novel modulator for endothelial adhesion molecules: adipocyte‐derived plasma protein adiponectin. Circulation 1999; 100: 2473–2476. - PubMed
    1. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, et al.: Adiponectin, metabolic risk fators, and cardiovascular events among patients with end‐stage renal disease. Am Soc Nephrol 2002; 13: 134–141. - PubMed
    1. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, et al.: Androgens decrease plasma adiponectin, an insulin‐sensitizing adipocyte‐derived protein. Diabetes 2002; 51: 2734–2741. - PubMed
    1. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al.: Weight reduction increases plasma levels of an adipose‐derived anti‐inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815–3819. - PubMed

Publication types

MeSH terms